Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.


Journal

RNA biology
ISSN: 1555-8584
Titre abrégé: RNA Biol
Pays: United States
ID NLM: 101235328

Informations de publication

Date de publication:
05 2019
Historique:
pmc-release: 05 03 2020
pubmed: 15 2 2019
medline: 27 11 2019
entrez: 15 2 2019
Statut: ppublish

Résumé

Acquired tamoxifen resistance is a persistent problem for the treatment of estrogen receptor positive, premenopausal breast cancer patients and predictive biomarkers are still elusive. We here analyzed gene expression changes in a cellular model to identify early and late changes upon tamoxifen exposure and thereby novel prognostic biomarkers. Estrogen receptor positive MCF-7 cells were incubated with 4OH-tamoxifen (10 nM) and gene expression analyzed by array hybridization during 12 weeks. Array results were confirmed by nCounter- and qRT-PCR technique. Pathway enrichment analysis revealed that early responses concerned mainly amine synthesis and NRF2-related signaling and evolved into a stable gene expression pattern within 4 weeks characterized by changes in glucuronidation-, estrogen metabolism-, nuclear receptor- and interferon signaling pathways. As a large number of long non coding RNAs was subject to regulation, we investigated 5 of these (linc01213, linc00632 linc0992, LOC101929547 and XR_133213) in more detail. From these, only linc01213 was upregulated but all were less abundant in estrogen-receptor negative cell lines (MDA-MB 231, SKBR-3 and UACC3199). In a web-based survival analysis linc01213 and linc00632 turned out to have prognostic impact. Linc01213 was investigated further by plasmid-mediated over-expression as well as siRNA down-regulation in MCF-7 cells. Nevertheless, this had no effect on proliferation or expression of tamoxifen regulated genes, but migration was increased. In conclusion, the cellular model identified a set of lincRNAs with prognostic relevance for breast cancer. One of these, linc01213 although regulated by 4OH-tamoxifen, is not a central regulator of tamoxifen adaption, but interferes with the regulation of migration.

Identifiants

pubmed: 30760083
doi: 10.1080/15476286.2019.1581597
pmc: PMC6546408
doi:

Substances chimiques

RNA, Long Noncoding 0
Receptors, Estrogen 0
Tamoxifen 094ZI81Y45

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-674

Références

Nature. 2000 Mar 23;404(6776):411-4
pubmed: 10746731
Clin Cancer Res. 2004 Apr 1;10(7):2336-43
pubmed: 15073109
Endocr Relat Cancer. 2004 Dec;11(4):643-58
pubmed: 15613444
Mol Cancer Ther. 2005 Jan;4(1):151-68
pubmed: 15657362
Nat Chem Biol. 2006 Apr;2(4):207-12
pubmed: 16520733
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9063-8
pubmed: 16754886
Mol Cell Endocrinol. 2008 Dec 16;296(1-2):1-9
pubmed: 18951949
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243
pubmed: 18980022
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Steroids. 2009 Jul;74(7):586-94
pubmed: 19138696
Nat Chem Biol. 2009 Jun;5(6):421-7
pubmed: 19430488
J Clin Oncol. 2009 Jul 20;27(21):3423-9
pubmed: 19487384
Lancet Oncol. 2009 Aug;10(8):825-33
pubmed: 19647203
Breast Cancer Res Treat. 2010 Aug;123(1):87-96
pubmed: 19911269
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Breast Cancer Res. 2009;11(6):112
pubmed: 20067604
Mol Endocrinol. 2010 Apr;24(4):709-21
pubmed: 20197310
Bioinformatics. 2010 Oct 1;26(19):2438-44
pubmed: 20709693
Breast Cancer Res Treat. 2011 Jul;128(2):457-66
pubmed: 21607586
Lancet. 2011 Aug 27;378(9793):747-9
pubmed: 21802719
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Oncogene. 2013 Feb 28;32(9):1173-82
pubmed: 22508479
Bioinformatics. 2012 Jun 1;28(11):1546-8
pubmed: 22513995
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
PLoS One. 2012;7(7):e41333
pubmed: 22844461
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Mol Oncol. 2013 Jun;7(3):611-24
pubmed: 23499324
Int J Oncol. 2013 May;42(5):1770-7
pubmed: 23525470
Eur J Pharmacol. 2013 Oct 5;717(1-3):47-57
pubmed: 23545365
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Breast Cancer Res Treat. 2013 May;139(1):71-80
pubmed: 23609470
Breast Cancer Res. 2013 Nov 29;15(6):R114
pubmed: 24289103
Sci Rep. 2014 Feb 17;4:4057
pubmed: 24531845
Science. 2014 Mar 28;343(6178):1452-3
pubmed: 24675948
Breast Cancer Res Treat. 2014 May;145(1):61-71
pubmed: 24715381
J Pathol. 2014 Aug;233(4):368-79
pubmed: 24752803
Front Endocrinol (Lausanne). 2014 May 06;5:66
pubmed: 24834064
Oncogene. 2015 Apr 9;34(15):1919-27
pubmed: 24882577
PLoS One. 2014 Jul 01;9(7):e101473
pubmed: 24983248
Breast Cancer Res Treat. 2014 Sep;147(2):423-31
pubmed: 25007959
Eur J Cancer. 2014 Nov;50(16):2866-76
pubmed: 25204804
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Pathol Res Pract. 2015 Mar;211(3):189-97
pubmed: 25666016
PLoS Comput Biol. 2015 Feb 23;11(2):e1004085
pubmed: 25706687
Am J Transl Res. 2015 Jan 15;7(1):120-7
pubmed: 25755834
J Mol Neurosci. 2015 Oct;57(2):197-202
pubmed: 26109525
Mol Cancer Ther. 2015 Nov;14(11):2411-21
pubmed: 26333382
Steroids. 2016 Jul;111:95-99
pubmed: 26884313
Biochim Biophys Acta. 2016 Jun;1860(6):1272-80
pubmed: 26971627
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Sci Rep. 2016 Jun 24;6:27931
pubmed: 27338266
Oncotarget. 2016 Aug 30;7(35):57239-57253
pubmed: 27528030
Cell Biol Toxicol. 2016 Dec;32(6):563-581
pubmed: 27585693
Nat Commun. 2016 Sep 26;7:12791
pubmed: 27666543
Pathology. 2017 Feb;49(2):111-119
pubmed: 28040199
Oncotarget. 2017 Mar 7;8(10):16642-16649
pubmed: 28186965
Nucleic Acids Res. 2017 Jul 3;45(W1):W130-W137
pubmed: 28472511
Mol Cancer. 2017 Oct 17;16(1):161
pubmed: 29041978
Endocr Relat Cancer. 2018 Apr;25(4):R259-R282
pubmed: 29440232
Sci Rep. 2018 Feb 16;8(1):3179
pubmed: 29453409
Oncologist. 2018 Aug;23(8):974-981
pubmed: 29934412
Breast Cancer. 2019 Mar;26(2):249-254
pubmed: 30066060
Noncoding RNA. 2018 Dec 12;4(4):null
pubmed: 30545127
Cancer Res. 1985 Apr;45(4):1525-31
pubmed: 3978620
Cancer Res. 1984 Nov;44(11):5038-45
pubmed: 6488162
Science. 1997 Jan 17;275(5298):343-9
pubmed: 8994024

Auteurs

Martin Porsch (M)

a Insitute of Computer Science , Martin Luther University Halle-Wittenberg , Halle , Germany.
b Institute of Human Genetics , Martin Luther University Halle-Wittenberg , Halle , Germany.
c German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig , Leipzig , Germany.

Esra Özdemir (E)

d Institute of Pathology, Otto von Guericke University Magdeburg , Magdeburg , Germany.

Martin Wisniewski (M)

d Institute of Pathology, Otto von Guericke University Magdeburg , Magdeburg , Germany.

Sebastian Graf (S)

a Insitute of Computer Science , Martin Luther University Halle-Wittenberg , Halle , Germany.

Fabian Bull (F)

a Insitute of Computer Science , Martin Luther University Halle-Wittenberg , Halle , Germany.
b Institute of Human Genetics , Martin Luther University Halle-Wittenberg , Halle , Germany.
c German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig , Leipzig , Germany.

Katrin Hoffmann (K)

b Institute of Human Genetics , Martin Luther University Halle-Wittenberg , Halle , Germany.

Atanas Ignatov (A)

e Department of Obstetrics and Gynecology , Otto von Guericke University Magdeburg , Magdeburg , Germany.

Johannes Haybaeck (J)

d Institute of Pathology, Otto von Guericke University Magdeburg , Magdeburg , Germany.
f Diagnostic and Research Institute of Pathology , Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz , Graz , Austria.
g Department of Pathology , Medical University of Innsbruck , Innsbruck , Austria.

Ivo Grosse (I)

a Insitute of Computer Science , Martin Luther University Halle-Wittenberg , Halle , Germany.
c German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig , Leipzig , Germany.

Thomas Kalinski (T)

d Institute of Pathology, Otto von Guericke University Magdeburg , Magdeburg , Germany.

Norbert Nass (N)

d Institute of Pathology, Otto von Guericke University Magdeburg , Magdeburg , Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH